However, we must keep in mind that the molecular hallmark in FRDA is the low expression of functional frataxin protein and therapeutic efforts have to be focused on attempting to increase FXN mRNA and/or protein amount [72]. This evidence concerns the gene FXN and Friedreich ataxia.